AU2020902574A0 - Treatment for covid-19 with rebamipide - Google Patents

Treatment for covid-19 with rebamipide

Info

Publication number
AU2020902574A0
AU2020902574A0 AU2020902574A AU2020902574A AU2020902574A0 AU 2020902574 A0 AU2020902574 A0 AU 2020902574A0 AU 2020902574 A AU2020902574 A AU 2020902574A AU 2020902574 A AU2020902574 A AU 2020902574A AU 2020902574 A0 AU2020902574 A0 AU 2020902574A0
Authority
AU
Australia
Prior art keywords
rebamipide
covid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020902574A
Inventor
Michael Lionel Selley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenexus Pharmaceuticals Pty Ltd
Original Assignee
Xenexus Pharmaceuticals Pty Ltd
Filing date
Publication date
Application filed by Xenexus Pharmaceuticals Pty Ltd filed Critical Xenexus Pharmaceuticals Pty Ltd
Publication of AU2020902574A0 publication Critical patent/AU2020902574A0/en
Pending legal-status Critical Current

Links

AU2020902574A 2020-07-23 Treatment for covid-19 with rebamipide Pending AU2020902574A0 (en)

Publications (1)

Publication Number Publication Date
AU2020902574A0 true AU2020902574A0 (en) 2020-08-06

Family

ID=

Similar Documents

Publication Publication Date Title
EP3781564A4 (en) Compounds for the treatment of cancer
EP4051360B8 (en) Biomedical device for arterial access
EP3962524A4 (en) Cancer treatment
EP3973964A4 (en) Quinoline derivative used for combination treatment of small cell lung cancer
EP3938514A4 (en) Compounds and methods for reducing kcnt1 expression
EP4117655A4 (en) Treatment methods
AU2020902574A0 (en) Treatment for covid-19 with rebamipide
EP3949990A4 (en) Medicament for treating cancer
EP4004013A4 (en) Dinucleotide compounds for treating cancers and medical uses thereof
EP3934632A4 (en) Esketamine for the treatment of depression
EP3923947A4 (en) Fgfr inhibitors for the treatment of cancer
EP3846797A4 (en) Use of delta-tocotrienol for treating cancer
EP4046683A4 (en) Mouthpiece-type treatment device
AU2020904714A0 (en) Treatment of covid-19 with rebamipide
AU2021902636A0 (en) Emissions treatment
AU2021900287A0 (en) Emissions Treatment
AU2020902015A0 (en) Emissions treatment
AU2020900782A0 (en) Treatment Methods
AU2021904108A0 (en) Treating COVID
EP3960143A4 (en) Treatment table
EP4025203A4 (en) Cancer treatment
AU2019900181A0 (en) Treatment
AU2020900675A0 (en) Combination Treatment for Microorganisms
AU2019903263A0 (en) Cancer treatment
AU2020900162A0 (en) Crosslinkable Polysiloxane